%0 Journal Article
%T Administraci¨®n oral de preparado parenteral de vitamina K en anticoagulaci¨®n excesiva por warfarina
%A Lozada
%A Yoleima
%A Falcone
%A Marinela
%A Granero
%A Ricardo
%J Medicina (Buenos Aires)
%D 2012
%I Fundaci¨®n Revista Medicina
%X anticoagulation therapy with warfarin, a common clinical practice, needs to be monitored using protombine time expressed as the international normalized ratio (inr); when safety range is exceeded, vitamin k (vit-k) could be administered with preference orally. in venezuela the specific oral preparation for vit-k is not available. this is a double blinded, randomized, placebo controlled, clinical trial; 20 patients, age 18-60 year with initial inr ¡Ý 6, ¡Ü10, were randomized to oral vit-k 1.25mg (prepared from intravenous presentation) or placebo plus withholding warfarin. inr < 3.5 at 24 hours of treatment (the primary end point) was achieved by 70% among vit-k, and 20% among placebo patients; given an absolute risk reduction (arr), of 50% (ci95%: 14.4-85.6) ¦Ñ = 0.028, nnt 2 (ci95%: 1.3 - 6.9). no adverse events were recorded including inr < 2 at 24 hours of treatment administration. our results are consistent with studies where specific oral presentation of vit-k was used. the results indicate that oral administration of vit-k, prepared from an intravenous vit-k preparation, is safe and more effective to revert excessive anticoagulation than simply withholding warfarin, in places where specific preparation of oral vit-k is not available or too expensive.
%K vitamin k
%K warfarin
%K oral administration
%K clinical trial
%K anticoagulation.
%U http://www.scielo.org.ar/scielo.php?script=sci_abstract&pid=S0025-76802012000200005&lng=en&nrm=iso&tlng=en